Uteron Pharma, a Belgian spin-out of Liège University, is facing the prospect of having to fire up to 30 employees. This would cut the company’s total staff in half.
The company had only been acquired by Actavis (then Watson Pharmaceuticals) in January 2013 for an upfront cash payment of $150m and a potential further $155m in milestone payments. Watson has since completed the change of its company brand to Actavis, following its acquisition of the eponymous group for €4.25bn ($7bn).
…
University venture funds are becoming an increasingly important tool for universities to support their ecosystems — here are the new ones launched in 2024.
Global University Venturing (GUV) is where tech transfer, academic and investment experts meet to explore the latest ideas and technologies driving innovation forward. We drive the discussions and share best practices that are critical to the success of spinouts, scaleouts and innovation programmes. Our aim is to help improve the processes of bringing innovations from academia to global markets and facilitate their integration into the broader business ecosystem.
